Compare SNY & SBUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNY | SBUX |
|---|---|---|
| Founded | 1994 | 1971 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.4B | 105.7B |
| IPO Year | N/A | 1992 |
| Metric | SNY | SBUX |
|---|---|---|
| Price | $46.01 | $93.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 24 |
| Target Price | $61.50 | ★ $100.83 |
| AVG Volume (30 Days) | 4.7M | ★ 11.6M |
| Earning Date | 01-29-2026 | 01-28-2026 |
| Dividend Yield | ★ 3.48% | 2.64% |
| EPS Growth | ★ 44.16 | N/A |
| EPS | ★ 7.52 | 1.20 |
| Revenue | ★ $54,850,299,422.00 | $37,701,700,000.00 |
| Revenue This Year | $2.70 | $5.21 |
| Revenue Next Year | $6.84 | $5.50 |
| P/E Ratio | ★ $12.14 | $78.13 |
| Revenue Growth | ★ 5.49 | 4.30 |
| 52 Week Low | $44.62 | $75.50 |
| 52 Week High | $60.12 | $117.46 |
| Indicator | SNY | SBUX |
|---|---|---|
| Relative Strength Index (RSI) | 44.94 | 53.56 |
| Support Level | $47.39 | $90.62 |
| Resistance Level | $49.42 | $101.20 |
| Average True Range (ATR) | 0.74 | 3.17 |
| MACD | 0.08 | -0.17 |
| Stochastic Oscillator | 31.32 | 34.61 |
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Starbucks stands out as the world's biggest and most recognizable coffee brand, powered by ultracustomizable beverages in-store and a sweeping footprint of nearly 41,000 cafes in over 80 countries. About 52% are company-operated, with the balance run by licensees. The company operates roasteries and sells across its North America (74% of revenue as of the end of fiscal 2025), international (21%), and channel development (5%) segments. The brand collects revenue from company-operated stores, licensee royalties, equipment and product sales, retail ready-to-drink beverages, and packaged coffee.